[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"EBG MedAustron GmbH\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":90},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,44,68],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":33,"startDateStruct":36,"completionDateStruct":38,"leadSponsor":40,"locationsCount":43},"100454007","radiotherapy-for-locally-advanced-pancreatic-carcinomas-phase-ii-trial-100454007",false,"NCT05191940","Radiotherapy for Locally Advanced Pancreatic Carcinomas (Phase II Trial)","Phase II Trial of Hypo-fractionated Highly Conformal Radiotherapy for Locally Advanced Pancreatic Carcinomas","LAPC","Inclusion Criteria:\n\n1. The patient has histologically or cytological confirmed diagnosis of pancreatic cancer (cases with radiological findings suspicious of pancreatic cancer AND elevated CA 19-9 may be enrolled even without positive cytology)\n2. The patient is not candidate for radical surgical resection because of one or more of the following reasons:\n\n   1. the patient is staged as locally advanced and with unresectable disease according to the international consensus definition. Specific criteria are: there is involvement of portal vein\u002Fsuperior mesenteric vein with bilateral narrowing\u002Focclusion, exceeding the inferior border of the duodenum; or tumor contact\u002Finvasion of 180 or more degree of the superior mesenteric artery or of the truncus coeliacus; or tumor contact\u002Finvasion of the proper hepatic artery\u002F celiac artery; or tumor contact or invasion of the aorta.\n   2. the patient is not a candidate for radical surgery because of radiographic or biochemical (CA 19-9) progression during neoadjuvant chemotherapy despite being initially classified as resectable or borderline resectable according to the international consensus definition.\n   3. the patient is not candidate for radical surgery because of cN+ stage\n3. The patient is not candidate to (further) neoadjuvant chemotherapy because of one or more of the following reasons:\n\n   1. the patient is not fit for chemotherapy\n   2. the patient has progressed under chemotherapy\n   3. the patient has received neoadjuvant chemotherapy but is judged still not a candidate for explorative surgery.\n4. Negative staging for distant metastasis\n5. Age \\> 18 years\n6. Karnofsky index ≥ 70\n7. No tumor infiltration of stomach or duodenum\n8. The patient is informed of the diagnosis and is able to give informed consent (Ability of patient to understand character and individual consequences of the study protocol)\n9. Women of fertile age must have adequate conception prevention measures and must not breast feed\n10. Signed Informed Consent (must be available before study inclusion)\n\nExclusion Criteria:\n\n1. Non-exocrine tumors\n2. Major medical or psychiatric comorbidities that contraindicate radiotherapy\n3. Presence of distant metastasis\n4. Pregnancy or unwilling to do adequate conception prevention\n5. Lactating and unwilling to discontinue lactation\n6. Men of procreative potential not willing to use effective means of contraception\n7. Metallic prosthesis or other conditions - IF it prevents an adequate imaging for target volume definition or treatment planning at the discretion of the treating institution contraindicate radiotherapy e.g. active infections in the area\n8. Previous abdominal radiotherapy\n9. Severe hepatic or renal impairment at discretion of treating institution\n10. Patient refusal","ALL","18 Years",{"count":20,"type":21},30,"ESTIMATED","INTERVENTIONAL",[24],"NA","This is an interventional, single-arm, open-label study with high dose short course radiotherapy for patients with locally advanced pancreatic cancer.",[27],"Pancreas Cancer",[29,30],"Particle Radiotherapy","Hypofractionated radiotherapy","RECRUITING","2026-03-19",{"date":34,"type":35},"2026-03-20","ACTUAL",{"date":37,"type":35},"2022-05-16",{"date":39,"type":21},"2028-12",{"name":41,"class":42},"EBG MedAustron GmbH","INDUSTRY",1,{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":48,"acronym":49,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":51,"targetDuration":4,"studyType":22,"phases":53,"briefSummary":54,"conditions":55,"keywords":58,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":61,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":67},"100431173","preoperative-proton--radiotherapy-combined-with-chemotherapy-for-borderline-resectable-pancreatic-cancer-100431173","NCT04894643","Preoperative, Proton- Radiotherapy Combined With Chemotherapy for Borderline Resectable Pancreatic Cancer","PARC","Inclusion Criteria:\n\n* Patients with histologically or cytologically confirmed diagnosis of pancreatic cancer\n* Diagnosis of borderline resectable cancer according to the international consensus definition 2017.\n* Negative staging for distant metastasis\n* Blood test within the following limits absolute neutrophil count \\> 1,500 cells\u002Fmm³, platelet count \\> 100,000 cells\u002Fmm³, Aspartate Aminotransferase (AST) and Alanine Aminotransferase (ALT) \\\u003C 2.5 times the upper limit of normal, total bilirubin \\\u003C 2.5 times the upper limit of normal if patient had recent biliary stenting, total bilirubin \\\u003C 1.5 times the upper limit of normal if no biliary stenting was done, serum creatinine within normal range (0.6-1.5 mg\u002Fdl) with a creatinine clearance \\> 30 ml\u002Fmin (as estimated by Cockroft Gault equation)\n* Age \\> 18 years\n* Karnofsky index ≥ 70\n* No tumor infiltration of stomach or duodenum\n* The patient is informed of the diagnosis and is able to give informed consent (Ability of subject to understand character and individual consequences of the study protocol)\n* Women of fertile age must have adequate conception prevention measures and must not breast feed\n* Signed Informed Consent (must be available before study inclusion)\n\nExclusion Criteria:\n\n* Non-exocrine tumors\n* Major medical or psychiatric comorbidities that contraindicate radiation therapy, chemotherapy or surgery\n* Presence of distant metastasis\n* Pregnancy or unwilling to do adequate conception prevention\n* Lactating and unwilling to discontinue lactation\n* Men of childbearing potential not willing to use effective means of contraception\n* Known allergic\u002Fhypersensitivity reaction to any of the components of study treatments\n* Previous diagnosis of another neoplasm with worse prognosis as compared with the one in this study\n* Metallic prosthesis or other condition that prevent an adequate imaging for target volume definition\n* Loco-regional conditions that contraindicate radiotherapy e.g. active infections in the area\n* Previous abdominal radiotherapy\n* Prior systemic treatment for pancreatic cancer\n* Hypersensitivity to PACLitaxel, albumin, gemcitabine or to any of the excipients of the chemotherapy\n* Severe hepatic impairment\n* Baseline Neutrophil Counts \\\u003C 1.5 x 10\\^9\u002FL\n* Baseline Grade ≥ 2 sensory or motor neuropathy\n* Patient refusal",{"count":52,"type":21},10,[24],"This is an interventional, single arm, open-label, feasibility trial with gemcitabine and nab-paclitaxel, followed by concomitant proton therapy and capecitabine, followed by re-evaluation and surgery (when feasible) for patients with borderline resectable pancreatic cancer.",[56,57],"Pancreatic Cancer","Proton Therapy",[59,60],"Proton therapy combined with chemotherapy","Borderline Resectable Pancreatic Cancer",{"date":34,"type":35},{"date":63,"type":35},"2020-09-14",{"date":65,"type":21},"2027-12-31",{"name":41,"class":42},2,{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":74,"eligibilityCriteria":75,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":76,"targetDuration":78,"studyType":79,"phases":4,"briefSummary":80,"conditions":81,"keywords":4,"overallStatus":31,"whyStopped":4,"lastUpdateSubmitDate":32,"lastUpdatePostDateStruct":83,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":43},"100289539","ion-therapy-patient-registry-100289539","NCT03049072","Ion Therapy Patient Registry","A Prospective Registry Study to Record Clinical Results and Side Effects of Ion Beam Therapy at MedAustron","REGI-MA-002015","Inclusion Criteria:\n\n* Patients with tumor disease treated with ion beam therapy at MedAustron\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Comorbidities endangering treatment delivery or study compliance",{"count":77,"type":21},2800,"10 Years","OBSERVATIONAL","The purpose of the study is the prospective and standardized data collection of patients treated with ion therapy at MedAustron.",[82],"Ion Beam Radiation Therapy for Tumor Patients",{"date":84,"type":35},"2026-03-23",{"date":86,"type":35},"2016-12",{"date":88,"type":21},"2036-12",{"name":41,"class":42},""]